|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The PI3K/AKT pathway is activated through PIK3CA or AKT1 mutations and PTEN loss in breast cancer.
|
31277699 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Regulation of AKT phosphorylation by GSK3β and PTEN to control chemoresistance in breast cancer.
|
31006103 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our previous study indicated that MEOX1 is a critical molecular target in mesenchymal-like cancer cells in PTEN-deficient Trastuzumab resistant breast cancer.
|
30662330 |
2019 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We report a germline mutation of the PTEN (c.723dupT, exon 7) identified in a young woman with a simultaneous occurrence of breast cancer, dermatofibrosarcoma protuberans, and follicular neoplasm.
|
29510612 |
2019 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Epithelial to mesenchymal transition (EMT) is a process in which epithelial cells lose cell polarity and cell-cell adhesion and gain migratory and invasive properties to become mesenchymal cells that are very vital for development, wound healing and stem cell behavior and contribute pathologically to fibrosis and cancer progression. miR21, a potent regulator of the tumor suppressor gene PTEN, can be silenced to reverse EMT, thereby providing an attractive target for abrogating the malignant behavior of breast cancer.
|
30109002 |
2018 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
|
29567542 |
2018 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
|
29110152 |
2018 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
|
30096458 |
2018 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we investigated the effects of 15d-PGJ<sub>2</sub> on the activity of PTEN, the inhibitor of the phosphoinositide 3-kinase (PI3K)-Akt axis, in human breast cancer (MCF-7) cells.
|
29550515 |
2018 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, high Notch-1 and low PTEN mRNA expression may predict poorer overall survival in women with breast cancer.
|
29743588 |
2018 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The over-expression of certain receptors (ER, PgR, HER-2, VEGF-R), as well as alteration of several intracellular signal transduction pathways (the PI3K-AKT-mTOR pathway, MEK-MAPK pathway, loss of PTEN, etc ...) has a great impact on the likelihood of recurrence and progression of the disease, influencing the natural history of breast cancer.
|
28183251 |
2018 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In this study, we perform a comprehensive analysis to investigate the effect of PTEN and SHIP gene expression on regulating lymph node metastasis in breast cancer.
|
30539826 |
2018 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, the synthetically lethal interaction between PTEN and ATM in breast cancer has not been reported.
|
29522753 |
2018 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
miR-19 targeting of PTEN mediates butyl benzyl phthalate-induced proliferation in both ER(+) and ER(-) breast cancer cells.
|
29864457 |
2018 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
PTENP1 performed a negative role in the development of BC via downregulating miR-19 probably through the PTEN/PI3K/Akt pathway.
|
29212574 |
2018 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Various stimuli can increase pAKT levels and elevated basal pAKT levels are a feature of PTEN-deficient breast cancer cell lines.
|
29438745 |
2018 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Combined, these data indicate that diagnostic or therapeutic chest radiation may predispose patients with decreased stromal PTEN expression to secondary breast cancer, and that prophylactic EGFR inhibition may reduce this risk.
|
30018330 |
2018 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Since TQ has been reported to up-regulate several growth factors such as vascular endothelial growth factor (VEGF), EGF and PTEN expression, the present review article discusses the targeting potential of TQ for therapeutic intervention against such types of breast cancer.
|
28606050 |
2018 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Also, primary breast cancer specimens, all ER positive and HER2 negative, were immunohistochemically investigated for phospho-S6 (pS6) and PTEN, to evaluate the mTOR and PIK3CA/Akt pathways.
|
29520681 |
2018 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Cellular levels of p-AKT(Ser473/Thr308) and p-ERK1/2(Thr202/Tyr204), activating mutations of PIK3CA and inactivating mutations of PTEN may predict response to everolimus in breast cancer cells; these findings have potential applications for treatment personalization of everolimus in breast cancer patients.
|
29476223 |
2018 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Some of the tagging single-nucleotide polymorphisms of 5 genes ( PALB2, TP53, Nijmegen breakage syndrome 1, PTEN, and BRCA1-interacting protein 1) involved in the monoubiquitinated FANCD2-DNA damage repair pathway were significantly associated with breast cancer risk.
|
30799775 |
2018 |
|
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings suggest that functional interaction between Plac1 and Furin enhances breast cancer invasion and metastasis and the Furin/NICD/PTEN axis may act as an important therapeutic target for breast cancer treatment.
|
29704427 |
2018 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The objective of our study was to correlate the immunohistochemical expression of PTEN in the four major subtypes of breast carcinoma (Luminal A, Luminal B, HER2 positive, and Triple Negative) in a population of 202 African-American (AA) females with other clinicopathological factors.
|
29653745 |
2018 |
|
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We demonstrate the utilities of iTextMine with two use cases involving the gene PTEN and breast cancer and the gene SATB1.
|
30576489 |
2018 |
|
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, HOTAIR could bind specifically to EZH2 and PTEN, highlighting the capability of HOTAIR to inhibit the expression of PTEN by recruiting EZH2 in breast cancer, while the TCGA database demonstrated the expressions of PTEN were lower in breast cancer cells.
|
30048163 |
2018 |